Truist Financial reaffirmed their buy rating on shares of Amneal Pharmaceuticals (NYSE:AMRX – Free Report) in a report released on Wednesday, Benzinga reports. The firm currently has a $6.00 target price on the stock. Other equities analysts also recently issued research reports about the company. Barclays increased their price target on Amneal Pharmaceuticals from $4.00 […]